Clinical Trial Update: The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for HLX208 in advanced anaplastic thyroid cancer with BRAF V600 mutation across Phase 1/Phase 2 cohorts; status is currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Cancer

Drugs mentioned

• HLX208

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Anaplastic Thyroid Cancer, ATC | Phase 1, Phase 2 | Status: UNKNOWN